Miconvey Medical announces acquisition of Huaiyin Medical in bid to become top 5 minimally invasive surgery device player in China

Recently, Miconvey Medical announced that it has entered into a cooperation agreement with Fosun Diagnostics to acquire 100% equity of Huaiyin Medical, a subsidiary of Fosun Diagnostics. Siche Consulting served as the exclusive financial advisor for this transaction.

Founded in 1959, Huaiyin Medical is one of the earliest surgical suture manufacturers in China. The company has built a diversified product portfolio covering nearly 1,000 specifications, including absorbable surgical sutures, non-absorbable surgical sutures, and surgical blades. Its products are sold in more than 40 countries and regions worldwide, consistently providing high-quality surgical instrument solutions for clinical use both domestically and internationally.

This transaction represents a key strategic move for Miconvey Medical as it strives to break into the top tier of domestic minimally invasive surgical device manufacturers in China, marking a new phase of development driven by the dual engines of "organic growth + external M&A," transitioning from a purely organic growth model.

Founded in 2013, Miconvey Medical focuses on the field of minimally invasive surgical instruments. In the face of the early Chinese domestic market being dominated by overseas brands, the company has deeply cultivated its core technologies and built an integrated system covering R&D, manufacturing, and sales. Its core products have obtained authoritative certifications from major global markets including NMPA, CE, and FDA, forming three core product lines: ultrasonic cutting and hemostasis systems, staplers, and collagen sponges.

Miconvey Medical's rapid growth is largely attributed to its innovative business model and differentiated product strategy. The company has now been recognized as a National High-Tech Enterprise and a National "Little Giant" Specialized and Sophisticated Enterprise.

In the Chinese domestic market, Miconvey Medical's core products have been awarded bids in multiple centralized procurement projects, driving rapid business growth. In overseas markets, Miconvey Medical has established a strong presence in multiple countries and regions, striving to build an international brand, with products exported to more than 50 countries and regions worldwide.

Looking ahead, Miconvey Medical's strategy will steadily advance along three fronts. First, strengthening organizational capabilities. Chairman Lan Jianhua has stated that "people" are the key factor in organizational development, and Miconvey Medical will continue to build a process-oriented and project-based organization. Second, upgrading the business model. Miconvey Medical focuses on four major areas — thoracic surgery, general surgery, urology, and gynecology — to create comprehensive solutions centered around clinical departments and surgical procedures, transitioning from "selling products" to "selling solutions." Third, enriching the product pipeline. This will be achieved by accelerating clinically-driven R&D innovation to drive product iteration and launch more innovative products, while also continuously expanding the pipeline through external M&A, licensing, and contract R&D.